These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 32942347)

  • 1. Naloxone-Induced Acute Opioid Withdrawal in a Stabilized Extended-Release Naltrexone-Treated Patient.
    Spitzberg AJ; Urner EM; Wirshing WC
    Prim Care Companion CNS Disord; 2020 Sep; 22(5):. PubMed ID: 32942347
    [No Abstract]   [Full Text] [Related]  

  • 2. Precipitated withdrawal during maintenance opioid blockade with extended release naltrexone.
    Fishman M
    Addiction; 2008 Aug; 103(8):1399-401. PubMed ID: 18855831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute opioid withdrawal precipitated by ingestion of crushed embeda (morphine extended release with sequestered naltrexone): case report and the focused review of the literature.
    Ruan X; Chen T; Gudin J; Couch JP; Chiravuri S
    J Opioid Manag; 2010; 6(4):300-3. PubMed ID: 20862910
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A clinical trial to determine if corelease of morphine and naltrexone from crushed extended-release capsules induces withdrawal in opioid-dependent patients: a descriptive analysis of six patients.
    Setnik B; Roland CL; Goli V; Sommerville K; Webster L
    J Opioid Manag; 2013; 9(2):139-50. PubMed ID: 23709323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Severe opioid withdrawal syndrome after a single dose of nalmefene.
    Donnerstag N; Schneider T; Lüthi A; Taegtmeyer A; Raetz Bravo A; Mehlig A
    Eur J Clin Pharmacol; 2015 Aug; 71(8):1025-6. PubMed ID: 26050241
    [No Abstract]   [Full Text] [Related]  

  • 6. Withdrawal syndrome after co-medication of opioid maintenance therapy with nalmefene: unrecognized interaction.
    Diot C; Eiden C; Roussin A; Batisse A; Boucher A; Chavant F; Daveluy A; Donadieu-Rigole H; Peyrière H;
    Eur J Clin Pharmacol; 2015 Dec; 71(12):1539-40. PubMed ID: 26329380
    [No Abstract]   [Full Text] [Related]  

  • 7. Safety of EMBEda (morphine sulfate and naltrexone hydrochloride) extended-release capsules: review of postmarketing adverse events during the first year.
    Badalamenti VC; Buckley JW; Smith ET
    J Opioid Manag; 2012; 8(2):115-25. PubMed ID: 22616317
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prolonged-release naloxone can cause systemic opioid withdrawal.
    Wilcock A
    Eur J Pain; 2009 Oct; 13(9):1001; author reply 1002-3. PubMed ID: 19615925
    [No Abstract]   [Full Text] [Related]  

  • 9. Naldemedine-induced Opioid Withdrawal Syndrome in a Patient with Breast Cancer without Brain Metastasis.
    Ishii K; Yamashita H; Yamaguchi M; Komatsu Y; Ryu E; Morishita S; Matsuo K; Kamada M; Ikeda T; Ashizawa K; Hara T
    Intern Med; 2020 Jan; 59(2):293-296. PubMed ID: 31534081
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nalmefene Mistakenly Prescribed to Reduce Alcohol Consumption in Patients Under Buprenorphine Substitution Therapy Resulting in Acute Opioid Withdrawal: Management in an Emergency Setting.
    Pélissier F; Rougé Bugat ME; Nubukpo P; Franchitto N
    J Clin Psychopharmacol; 2016 Feb; 36(1):100-3. PubMed ID: 26658085
    [No Abstract]   [Full Text] [Related]  

  • 11. Severe withdrawal from short-term transdermal fentanyl after naloxone for uremic pruritus.
    Finsterer J; Keller H; Arias I; Zuntner G
    J Pain Symptom Manage; 2004 May; 27(5):387-8. PubMed ID: 15120761
    [No Abstract]   [Full Text] [Related]  

  • 12. Intraoperative high-dose remifentanil in a patient on naltrexone therapy.
    Schwab CA; Wright DA
    Anaesth Intensive Care; 2000 Dec; 28(6):701-3. PubMed ID: 11153302
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Opioid withdrawal syndrome after treatment with low-dose extended-release oxycodone and naloxone in a gastric cancer patient with portal vein thrombosis.
    Kang JH; Lee GW; Shin SH; Bruera E
    J Pain Symptom Manage; 2013 Aug; 46(2):e15-7. PubMed ID: 23680581
    [No Abstract]   [Full Text] [Related]  

  • 14. Withdrawal syndrome is not precipitated when butorphanol is added to opiate or opioid therapy. A comment on intranasal butorphanol-induced apraxia reversed by naloxone.
    Barkin RL
    Pharmacotherapy; 1996; 16(5):969. PubMed ID: 8888097
    [No Abstract]   [Full Text] [Related]  

  • 15. Course and treatment of buprenorphine/naloxone withdrawal: an analysis of case reports.
    Westermeyer J; McCance-Katz EF
    Am J Addict; 2012; 21(5):401-3. PubMed ID: 22882389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Naltrexone- or Nalmefene-Related Buprenorphine Withdrawal: Treat It With… More Buprenorphine.
    Lescut C; Gaboriau L; Carton L; Rolland B
    J Clin Psychopharmacol; 2017 Oct; 37(5):631-633. PubMed ID: 28806388
    [No Abstract]   [Full Text] [Related]  

  • 17. Nalmefene nasal spray (Opvee) for reversal of opioid overdose.
    Med Lett Drugs Ther; 2023 Oct; 65(1687):166-167. PubMed ID: 37871116
    [No Abstract]   [Full Text] [Related]  

  • 18. The diverse clinical uses of opioid receptor drugs.
    Howland RH
    J Psychosoc Nurs Ment Health Serv; 2010 May; 48(5):11-4. PubMed ID: 20415289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unintentional rapid opioid detoxification.
    Quigley MA; Boyce SH
    Emerg Med J; 2001 Nov; 18(6):494-5. PubMed ID: 11696513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Withdrawal syndrome caused by naltrexone in opioid abusers.
    Hassanian-Moghaddam H; Afzali S; Pooya A
    Hum Exp Toxicol; 2014 Jun; 33(6):561-7. PubMed ID: 23690227
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.